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Abstract
Background: In Malta, off-label prescribing of medicines in children stands at 45%, mainly because of failure by prescribers to
follow the dosing recommendations in the product literature. In addition, registration procedures of pharmaceuticals may
inadvertently contribute to this high incidence of off-label prescribing. Methods: A literature review was conducted to identify
regulatory provisions relating to the registration of medicines in Malta that could give rise to off-label use. Furthermore, the
product literature of the 2 classes of medicines most commonly prescribed in children, antibiotics and respiratory medicines,
were reviewed. This was done in order to gauge whether the different registration routes implemented in Malta to market
these medicines could give rise to off-label use. Results: The national registration procedure relating to Article 126a of
Directive 2001/83/EC and, to a lesser extent, line extensions, parallel importation, and the provision detailed in Article 11 of
Directive 2001/83/EC were found to lead to discrepancies and potentially misleading inclusions in the product literature. These, in
turn, may well contribute to off-label use of medicines in children. Conclusions: Off-label prescribing does not necessarily mean that
efficacy and safety data are unavailable. Variances in the product literature of medicines having the same active ingredients but
imported from different countries may cause divergent prescribing practices, leading to inadvertent off-label use. The various
stakeholders, including member states such as Malta, should devise strategies to harmonize the most recent labeling information in
order to support the safe and effective use of pediatric medicines, thereby decreasing off-label use.
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Introduction
Article 179 of the Treaty on the functioning of the European
Union (EU) states that ‘‘the Union shall have the objective of
strengthening its scientific and technological bases by achiev-
ing a European research area in which researchers, scientific
knowledge and technology circulate freely, and encouraging it
to become more competitive, including in its industry, while
promoting all the research activities deemed necessary by vir-
tue of other Chapters of the Treaties.’’1 In this respect, Eur-
opean legislation aims to ensure that safe, good-quality and
efficacious medicinal products are freely marketed within the
EU.
Medicines for human use are marketed in a member state
after a marketing authorization has been granted. This regula-
tory requirement traces its origins to Council Directive 65/65/
EEC of January 26, 1965, which laid down the 3 basic criteria
on which marketing authorizations are based: quality, safety
and efficacy.2,3 In Malta, the smallest member state of the EU,
pharmaceutical regulation is governed by the Licensing
Authority, which is the Maltese competent authority, enacted
through the Medicines Act (Act III of 2003).4
European legislation details 2 types of authorization routes,
European and national, used to approve medicines in member
states. European procedures include the centralized authoriza-
tion procedure, mutual recognition procedure, and decentra-
lized procedure. These procedures involve the simultaneous
placing of medicines in different member states. In order to
obtain a community authorization across all Europe through the
centralized authorization procedure, the marketing authoriza-
tion holder needs to submit a marketing authorization
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application to the European Medicines Authority (EMA). Med-
icinal products authorized through the centralized authorization
procedure can be automatically marketed in all member states,
including Malta. The marketing authorization holder may also
opt for a decentralized procedure to obtain a marketing author-
ization in specific member states. However, when a medicinal
product is already authorized in a member state and the mar-
keting authorization holder needs to market it in other member
states, the mutual recognition procedure applies. In the case of
decentralized and mutual recognition procedures, an applica-
tion needs to be submitted by the marketing authorization
holder to the competent authority of those member states in
which the marketing authorization holder intends to market the
product.
Apart from these European procedures, which involve a
number of member states, there are also national authorization
mechanisms used by individual member states to register med-
icinal products in their territory. The principal national regis-
tration procedures used by the Maltese Licensing authority are
line extensions, parallel importation, and the provision gov-
erned by article 126a of Directive 2001/83/EC.5 Line exten-
sions are marketing authorizations granted to medicines as
detailed in Annex I of Commission Regulation (EC) No.
1234/2008.6 These include instances where there are changes
to the active ingredient, strength, pharmaceutical form, and
route of administration of medicinal products which are already
authorized in a particular member state. On the other hand,
parallel importation is governed by the Commission Commu-
nication on parallel imports of proprietary medicinal products
for which marketing authorizations have already been granted
(COM(2003) 839 final).7 Parallel importation is the importa-
tion of a specific medicinal product, already authorized in a
particular member state, from another member state, by a
wholesale dealer other than the officially appointed wholesale
dealer authorized by the marketing authorization holder. In
Malta, parallel importation is regulated by the Parallel Impor-
tation of Medicinal Products Regulations (458.40).8 The ratio-
nale for parallel importation arises from cross-country price
variability between source and destination countries for the
same medicinal product. A third national registration procedure
is based on article 126a of Directive 2001/83/EC, also referred
as the ‘‘Cyprus clause.’’ Article 126a states that ‘‘in the absence
of a marketing authorisation or of a pending application for a
medicinal product authorized in another Member State in
accordance with this Directive, a Member State may for justi-
fied public health reasons authorise the placing on the market
of the said medicinal product.’’2 Article 126a of Directive
2001/83/EC has been transposed in Malta as Article 3(2a) of
the Medicines (Marketing Authorisation) Regulations (SL
458.34).9
In order to gain either a European or national marketing
authorization, the marketing authorization holder needs to sub-
mit specific documentation to the competent authority as part
of the marketing authorization application. This includes the
summary of product characteristics and the patient leaflet. The
summary of product characteristics, whose content and struc-
ture are defined in Directive 2001/83/EC, is an important legal
document since it provides guidance on the appropriate use of a
particular medicinal product. In particular, section 4.1 of the
summary of product characteristics specifies the therapeutic
indications including the age groups in which the medicinal
product is indicated and section 4.2 relates to the posology,
specifying the dose recommendations for each age band
detailed in section 4.1.10
When prescribers recommend the use of a medicine in ways
other than those detailed in the summary of product character-
istics, this constitutes off-label use. The only European legis-
lation text that defines off-label use is Directive 2001/82/EC,
relating to veterinary medicines.11 It defines off-label use as
‘‘the use of a veterinary medicinal product that is not in accor-
dance with the summary of the product characteristics, includ-
ing the misuse and serious abuse of the product.’’12 The only
other non-legislative document which defines off-label use of
medicines in humans is Annex I to the Guideline on good
pharmacovigilance practices, published in 2014 by EMA. It
defines off-label use as ‘‘situations where a medicinal product
is intentionally used for a medical purpose not in accordance
with the authorised product information. Off-label use includes
use in non-authorised paediatric age categories.’’13
The principal European initiative to address off-label use
has been the adoption of Regulation (EC) No 1901/2006 (Pae-
diatric Regulation).14 This regulation, which came into force in
2007, effectively managed to increase the number of registered
pediatric medicines as well as improve the information on the
use of medicinal products in children.15 Nonetheless, recent
population studies conducted in various European countries
reveal that the incidence of pediatric off-label prescribing in
primary care ranges 11% to 51%.16,17 In a recently published
drug utilization study, Ellul et al reported the incidence of off-
label pediatric use of medicines in Malta to be 45%,18 citing the
failure by prescribers to follow the recommendations detailed
in the summary of product characteristics as one of the princi-
pal contributing factors. Pursuant to this, Ellul et al found that
this was mainly caused by inconsistencies in the summaries of
product characteristics. Although medicines may be identical
with respect to the active ingredient and formulation, if mar-
keted by different marketing authorization holders, the infor-
mation found in the summaries of product characteristics may
differ, leading to off-label prescribing by physicians.18,19
One of the most compelling illustrations of inconsistencies
in the product literature that has given rise to off-label use
concerns etanercept powder for injection. The summary of
product characteristics of etanercept, centrally authorized by
EMA, includes as an indication the treatment of juvenile idio-
pathic arthritis (JIA) in patients ‘‘who have had an inadequate
response to, or who have proved intolerant of, methotrexate.’’20
However, this indication was approved by EMA before meth-
otrexate was actually licensed for the treatment of JIA.21,22 In
view of this fact, for a number of years, the summary of product
characteristics of etanercept encouraged the off-label use of
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methotrexate in JIA, since methotrexate was not licensed for
the treatment of JIA. However, it is important to consider that
the safety and efficacy of methotrexate in JIA has been well
documented for many years, even before this indication was
effectively included in the summary of product characteristics
of methotrexate.22
This example clearly demonstrates that the use of medicines
in an off-label manner does not necessarily mean that evidence
on the safety and effectiveness of medicines is unavailable. In
fact, it has been proposed that failure to use medicines in an off-
label manner in specific scenarios, under the appropriate stan-
dard of care, can translate into malpractice, since this would
constitute the most rational clinical decision to take, when one
considers the risk-benefit ratio and lack of suitable alterna-
tives.23-25
Research Question, Hypothesis, and Aim
Off-label prescribing has been reported to primarily stem from
the lack of harmonization in the product literature which leads
to variable prescribing habits in children. The research question
was thus whether the registration procedures of medicines used
in Malta actually create an idiosyncratic setting whereby prod-
uct literatures of medicines relating to the same active ingre-
dient(s) are effectively licensed with divergent information.
The hypothesis which entailed was that specific registration
procedures in Malta inadvertently give rise to off-label use of
medicines in children. The aim was to identify those legislative
provisions that regulate the registration of medicines in such a
way as to lead to discrepancies in the product literature.
Methods
A literature review was conducted in Pubmed-Medline to
investigate any reported instances where registration proce-
dures implemented by member states could have inadvertently
led to off-label use of medicines. The following term associa-
tions in the title were used: ‘‘(Off-label[title/abstract]) AND
(Registration[title] OR mutual recognition [title] OR decentra-
lised procedure [title] OR centralised procedure [title] OR line
extension [title] OR parallel importation [title] OR national
[title] OR 126 [title] OR European Union [title] OR Europe
[title] OR Member State [title]).’’
A literature review of pharmaceutical legislation governing
both European and Maltese registration procedures was also
carried out. European legislation was accessed at EudraLex,
a web portal that contains legislative texts governing medicines
in the EU (ec.europa.eu/health/documents/eudralex). Further-
more, European guidance documents and relevant published
documents were reviewed in the web portals of the EMA
(ema.europa.eu) and the Co-ordination group for Mutual rec-
ognition and Decentralised procedures–human (CMDh;
hma.eu/cmdh.html). Maltese pharmaceutical legislation was
accessed at Justice Services, a web portal that contains legis-
lative texts in Malta (justiceservices.gov.mt). The web portal of
the Maltese Licensing authority (medicinesauthority.gov.mt)
was also reviewed for any relevant guidance documents.
In the study investigating the off-label incidence of pediatric
medicines,18 Ellul et al found that the respiratory system and
antibiotics were the most commonly prescribed drugs in chil-
dren in Malta. Similar findings have been reported by other
investigators.26-31 In view of this fact, the authors reviewed the
product literature of those respiratory medicines and antibiotics
that had been prescribed in an off-label manner in the study by
Ellul et al.18 These medicines were classified according to the
Anatomical Therapeutic Chemical (ATC) system by using the
Guidelines for ATC classification and Defined Daily Dose
assignment.32 Subsequently, the product literature, containing
the same active ingredient(s) but produced by different mar-
keting authorization holders, were compared with each other to
screen for inconsistencies between them. This was done in
order to review whether and how different registration proce-
dures used for these medicines contributed to divergences in
the product literature and subsequently to off-label use by pre-
scribers. Similarly to the study by Ellul et al,18 off-label use of
medicines was defined as instances when medicines are not
prescribed in accordance with their summary of product char-
acteristics with respect to age, dose, indication as well as fre-
quency, duration, and route of administration.
Results
Pubmed-Medline did not contain any publications that investi-
gated whether registration procedures adopted by the different
member states actually led to off-label use. During the review
of pharmaceutical legislation, the authors found that Article 11
of Directive 2001/83/EC could contribute to off-label prescrib-
ing of generic medicines in Malta. Furthermore, during the
literature review of respiratory medicines and antibiotics, the
authors identified 3 national registration mechanisms that
potentially led to inconsistencies in the product literature and,
subsequent to this, off-label use of medicines in children. These
are article 126a of Directive 2001/83/EC, line extensions, and
parallel importation.
Article 11 of Directive 2001/83/EC
Apart from governing the production, distribution and use of
medicinal products for human use within the EU, Directive
2001/83/EC also makes direct reference to intellectual prop-
erty. According to Article 11, when applying for a generic
marketing authorization in a specific member state through
either a European or national authorization route, ‘‘those parts
of the summary of product characteristics of the reference
medicinal product referring to indications or dosage forms
which were still covered by patent law at the time when a
generic medicine was marketed need not be included.’’2 The
purpose of this provision is the avoidance of delays in the
production of generic medicine. Article 11 has been transposed
in Malta as Article 8 of the Medicines (Marketing Authorisa-
tion) Regulations (SL 458.34).9
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In view of Article 11, in 2012, the co-ordination group for
mutual recognition and decentralized procedures recom-
mended the inclusion of a standard statement (blue-box) in the
patient leaflet of generic medicines, where applicable, ‘‘<active
substance> which is contained in <product> <may also be/is
also> authorised to treat other conditions which are not men-
tioned in this leaflet. Ask your doctor or pharmacist if you have
further questions.’’33 However, it is up to each member state to
decide whether a blue-box is required in the patient leaflet of
generic medicines marketed within their territory, where appli-
cable. In fact, only 6 member states require the inclusion of a
blue-box: Denmark, Finland, Iceland, the Netherlands, Nor-
way, and Sweden.34
Although Malta does not require the inclusion of a blue-box
in its product literature, it may still source medicines from
countries which require a blue-box. In fact, the authors have
identified medicines which have been registered in Malta and
whose marketing authorization holder is registered in Den-
mark, Iceland, the Netherlands, Norway, and Sweden. In view
of this fact, similarly to what might happen in these Nordic
countries, Maltese prescribers may interpret a blue-box to
imply that any generic medicines sourced from these countries
may be recommended for those patent-protected indications,
even if these indications are not mentioned in the product lit-
erature of the generic medicines. In this case, this may be
justified from a clinical and ethical perspective, since the
patent-protected indications would have been positively
reviewed by competent authorities in other member states, dur-
ing their registration phase. Nonetheless, when physicians pre-
scribe generic blue-box medicines for patent-protected
therapeutic indications, this would potentially give rise to
off-label use since the patent-protected indications would not
be included in the product literature of those same generic
medicines. Notwithstanding this, the authors found that the
relevance of this finding on off-label use of medicines is non-
significant for Malta since the number of medicines sourced
from Nordic countries is currently limited.
Article 126(a) of Directive 2001/83/EC
The cornerstone of the article 126a registration mechanism is
that the product literature of medicines authorized in Malta
through this procedure is identical to the product literature of
the reference medicine in another member state (country of
source). As such, medicinal products imported through an arti-
cle 126a provision need to have a valid marketing authorization
in the country of source and are marketed on the Maltese mar-
ket after the Licensing authority approves the English/Maltese
version of the product literature, that is, summary of product
characteristics, patient leaflet and outer carton. If the docu-
ments authorized in the country of source are not in English,
the product literature submitted to the Maltese Licensing
authority should be a notarized or certified English/Maltese
translation of the aforementioned documents. Although the
Licensing authority can technically issue numerous article
126a licenses to different wholesale dealers for the same med-
icinal product, sourced from different member states, this reg-
istration process should only be used for ‘‘justified public
health reasons’’ when other registration processes are not
feasible.35
Member states are also obliged to inform the European
Commission when they avail themselves of this provision. As
of March 29, 2016, according to the online list published by the
European Commission (ec.europa.eu/health/documents/com
munity-register/html/index_en.htm), only 7 member states
have used this provision to date: Lithuania (once), Portugal
(twice), Hungary (4 times), Latvia (5 times), Poland (12 times),
Cyprus (713 times), and Malta. According to the Maltese
Licensing Authority’s database (medicinesauthority.gov.mt),
as of March 29, 2016, 1877 out of 5025 medicines (37%)
available on the Maltese market had a valid article 126a
license. Medicines authorized through centralized authoriza-
tion procedures have not been included in this equation since
the great majority are not marketed in Malta. As such, Malta is,
by far, the most frequent user of this ‘‘Cyprus clause.’’ These
medicinal products have been sourced from Austria, Belgium,
Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, France,
Germany, Greece, Hungary, Ireland, Italy, Netherlands,
Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and the
United Kingdom. The manner in which Malta interpreted arti-
cle 126a of Directive 2001/83/EC allows it to issue numerous
article 126a authorizations for the same active ingredient. As an
example, currently there are 35 different article 126a author-
izations for simvastatin preparations. This approach has been
criticized by the Matrix Insight study, commissioned by the
European Commission.36 The Matrix Insight study states that
if a product containing a specific active ingredient has been
authorized by a member state, there is no public health need to
authorize additional products with the same active ingredient
through the article 126a registration route.
Medicines, containing the same active ingredient(s) and
imported from different member states via the article 126a
provision, can be authorized by the Maltese Licensing author-
ity with divergent product literatures. This stems from the fact
that different source countries may adopt differing posology
recommendations for the same active ingredient(s). The con-
fusing scenario that entails when prescribers recommend arti-
cle 126a medicines can be demonstrated by the following case.
Malta sources many medicines from the United Kingdom. In
fact, according to the Maltese Licensing Authority’s database
(medicinesauthority.gov.mt), as of 29 March 2016, 1705 out of
5025 medicines (34%) authorized in Malta have a marketing
authorization holder which is registered in the United King-
dom. Since 2010, the United Kingdom’s competent authority
(MHRA) increasingly started to restrict the use of specific
cough and cold medications for young children, including xylo-
metazoline, oxymetazoline, pseudoephedrine, guaifenesin,
diphenhydramine, promethazine, triprolidine, codeine, pholco-
dine and dextromethorphan. Taking as an example a product
sourced in Malta from the United Kingdom, containing
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dextromethorphan hydrobromide 7.5 mg/5 mL, when Maltese
physicians prescribe it for a child <12 years, it is considered to
be off-label for age. The reason for this is that, similarly to the
product found in the United Kingdom, the product literature
authorized in Malta specifies that it is licensed in children >12
years of age.37 However, the authors found that the product
literature of medicines sourced in Malta via the article 126a
procedure from member states, other than the United Kingdom,
can still recommend the use of such medicines in young chil-
dren. Thus, if a Maltese physician prescribes an article 126a
medicinal product, containing dextromethorphan hydrobro-
mide 15 mg/5 mL, triprolidine hydrochloride 1.25 mg/5 mL,
pseudoephedrine hydrochloride 20 mg/5 mL, and guaifenesin
100 mg/5 mL, originating from Cyprus, for a 2-year-old child,
this is not off-label. The reason for this is that the product
literature authorized in Malta specifies that it is licensed in
children >2 years of age.37
Physicians are generally familiar with one standard pre-
scribing regime for a particular active ingredient or combina-
tion of active ingredients. In fact, in a separate study, Ellul et al
found that divergent dosing recommendations, as seen above,
are interpreted by Maltese prescribers to mean that these med-
icines can still be safely prescribed in the younger age groups.38
In such cases, unintended off-label prescribing practices arise
because prescribers cross-refer to divergent product literatures
of medicines containing the same or similar ingredients. Fur-
ther to this, from a clinical perspective, cough and cold pre-
parations containing pseudoephedrine, dextromethorphan,
triprolidine, and guaifenesin were found to exhibit a negative
benefit-risk profile in young children. In keeping with this, the
United Kingdom’s MHRA recommended that medicinal prod-
ucts containing ‘‘illogical’’ combinations, such as antihista-
mines and expectorants, should be phased out.39 The BNF
for Children also specifies that the rationale for some com-
pound cough preparation is dubious, and that there is no evi-
dence that any drug can specifically facilitate expectoration.40
In conclusion, the use of cough and cold preparations in young
children may subject them to unnecessary adverse reactions
with no significant therapeutic benefit.
Line Extensions
This research also identified instances where medicines autho-
rized through line extensions exhibited divergent product lit-
eratures. This was caused because section 4.2 of the summary
of product characteristics was not updated by the marketing
authorization holder to reflect the most recent evidence-based
clinical practice guidelines. Subsequently, this caused a diver-
gence from the product literature of similar products within the
same therapeutic class. In view of this, when physicians pre-
scribe the medicinal product according to the most recent clin-
ical information, this would not be in line with the licensed
summary of product characteristics, and thus, this would con-
stitute off-label use. The following is an example. When Mal-
tese physicians prescribe 1 g co-amoxiclav tablets, sourced in
Malta from Cyprus, for a 10-year-old child weighing 40 kg, it is
considered to be off-label for age. The reason for this is that the
summary of product characteristics of this product, authorized
through a line extension, specifies that it is licensed in children
>12 years of age.37 However, if the same physician prescribes
another medicinal product containing 1 g co-amoxiclav,
sourced from Ireland, for the same child, this would not be
considered to be off-label. The reason for this is that the sum-
mary of product characteristics of this medicinal product spe-
cifies that it is licensed in children >40 kg.37
Pursuant to this finding, the authors found that in 2009, the
product literature of all co-amoxiclav preparations across all
member states were reviewed by EMA, through an Article 30
referral, in order to harmonize the product information. That
same year, EMA concluded that the posology recommenda-
tions should be revised to include weight considerations instead
of age considerations. Thus, use of the product in ‘‘adults and
children over 12 years’’ was changed to use in ‘‘adults and
children weighing 40 kg and over.’’41 However, when the
license of the above-mentioned Cypriot co-amoxiclav tablets
was renewed by the Maltese Licensing authority in 2012, the
posology section of the product literature was not streamlined
with the recommendations by EMA. This was found to lead to
off-label use of the Cypriot product in the pediatric population.
Interestingly, in 2012 the Maltese Ministry of Health acknowl-
edged that almost one in two Maltese children are overweight
or obese.42 Thus, it is highly likely that physicians encounter
cases where children who are <12 years weigh more than 40 kg.
Nonetheless, in view of the relatively small number of line
extensions granted in Malta, the significance of this finding
is limited.
Parallel Importation
Another national registration procedure which was found to
potentially contribute to off-label prescribing in Malta is par-
allel importation. Although the main benefit expected for this
practice is that patients avail themselves of a lower price of
medicines, it has been acknowledged that such benefit is prac-
tically nonexistent for Malta.43 The main reason for this is that
in the community setting, parallel imported medicines have
identical consumer prices to medicines that are not parallel
imported. Thus, financial benefits are principally intended for
parallel importers, and pharmacy owners who are offered better
bonuses by parallel importers in order to stock and dispense
their product.
Similar to article 126a products, medicines that are parallel
imported in Malta need to have a valid marketing authorization
in the country of source and are introduced on the Maltese
market after the Maltese Licensing authority approves the Eng-
lish/Maltese translation of the product literature. If the docu-
ments authorized in the country of source are not in English, the
product literature submitted to the Maltese Licensing authority
should be a notarized or certified English/Maltese translation of
the aforementioned documents.
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The parallel imported product should be identical to, or have
no significant therapeutic difference from, the medicine that
was initially authorized on the Maltese market.8 However,
from a regulatory perspective, the medicinal product that was
initially authorized on the Maltese market and the parallel
imported products are considered as separate medicinal prod-
ucts with separate sets of product literatures since they possess
separate licenses.
The Licensing authority can issue numerous parallel impor-
tation licenses to different wholesale dealers for medicines
sourced from different member states. According to the Mal-
tese Licensing Authority’s database (medicinesauthority.
gov.mt), as of March 29, 2016, a total of 309 out of 5025
medicines (6%) have been authorized in Malta via parallel
importation. Notwithstanding the fact that the composition is
identical, the authors found instances where the product litera-
tures of parallel imported medicinal products and the medicine
that was initially authorized on the Maltese market differed
slightly with respect to the posology recommendations. The
reason for such differences is that medicinal products may be
marketed in different member states with slightly different
product literatures. This is also a potential source of off-label
prescribing. However, in view of the nonsignificant posology
differences that have been identified between medicinal prod-
ucts that were initially authorized on the Maltese market and
their parallel imported products, the impact of parallel impor-
tation on off-label use of medicines in Malta is limited.
Discussion
With the exception of article 11 of Directive 2001/83/EC,
which also applies to European registration procedures, we did
not identify discrepancies in the product literature of medicines
authorized through European registration mechanisms, that is,
centralized authorization procedure, mutual recognition proce-
dure and decentralized procedure. The reason for this is that
such procedures entail the simultaneous review of the same
marketing authorization application, including the product lit-
erature, by various member states. Such thorough clinical
appraisal leads to harmonized summaries of product character-
istics and patient leaflets across all concerned member states.
On the other hand, the national registration procedures imple-
mented by Malta were found to potentially lead to differences
in the product literature of medicines containing the same
active ingredient, giving rise to off-label use. Of these, article
126a of Directive 2001/83/EC was found to be the main poten-
tial contributing factor for such differences.
European legislation provides for the free movement of
medicinal products between member states in order to optimize
the provision of health care, promote public health, and at the
same time safeguard intellectual property. In order to ensure an
adequate provision of pharmaceutical care, small member
states like Malta import almost all of their medicinal products
from other countries. Immediately following EU accession,
medicines available in Malta dropped by 83%. The reason for
this was that pharmaceutical companies did not consider it
pharmacoeconomically feasible to submit the required docu-
mentation to meet the regulatory requirements for them to
continue to sell medicines on the small Maltese market.36 This
caused shortages of many medicines, including pediatric ones.
Thus, in 2006 the Maltese Licensing authority implemented a
simpler national registration mechanism to mitigate these med-
icine shortages, that is, article 126a of Directive 2001/83/EC.
Article 126a was considered a better alternative to article 5(1)
of Directive 2001/83/EC as a route to register medicines
nationally, in cases where there are more than a few patients.43
Article 5(1) states, ‘‘A Member State may, in accordance with
legislation in force and to fulfil special needs, exclude from the
provisions of this Directive medicinal products supplied in
response to a bona fide unsolicited order, formulated in accor-
dance with the specifications of an authorized health-care pro-
fessional and for use by an individual patient under his direct
personal responsibility.’’2
The implementation of article 126a procedure was indeed
successful in that it reversed the steady decline in the registra-
tion of medicines in Malta. However, the raison d’etre of this
registration procedure is that the medicinal product, as autho-
rized in Malta, is identical to the reference product found in the
source country. As such, different member states may author-
ize, via national procedures, different clinical recommenda-
tions with respect to specific active ingredients in their
territories. This would result in important differences in sec-
tions 4.1 and 4.2 of the summary of product characteristics, as
well as in the information found within the patient leaflet. This
stance, which has been acknowledged by the European Com-
mission,44 means that following the registration procedure,
medicinal products may have different summaries of product
characteristics and package leaflets in different member states.
Subsequent to this, variable prescribing practices of the same
active ingredient may arise across different member states.
In Malta, numerous article 126a licenses may be granted to
medicines containing the same active ingredients. This means
that any divergent recommendations within the product litera-
ture of these medicines, as found in different member states, are
mirrored in the product literature licensed in Malta when these
medicines are registered in Malta. Considering that Malta is the
member state that, by far, has issued the most article 126a
authorizations (1877 licenses from 21 member states), this
finding is particularly significant. The authors found this reg-
istration route to be the main source of divergent information in
the product literature of pediatric medicines containing the
same active ingredients. When physicians cross-refer to differ-
ent product literatures, this leads to unintended off-label pre-
scribing in children. In fact, the ‘‘General Report on Experience
Acquired as a Result of the Application of the Paediatric Reg-
ulation,’’ published by the European Commission, acknowl-
edges the fact that physicians may not always realize or
consider that the manner in which they prescribe medicinal
products may, in fact, constitute off-label use.45
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In view of this, the European Commission has devised
mechanisms through which the product literature across differ-
ent member states can be harmonized. Such referral procedures
include Article 30 of Directive 2001/83/EC, used when ‘‘Mem-
ber States have adopted divergent decisions concerning the
authorization of the medicinal product or its suspension or
revocation.’’2 The Article 30 referral procedure is intended to
be used when member states adopt different recommendations,
including different indications, contraindications or posologies,
in the product literature. In this case, the only differences that
would be permitted relate to, example, the name of the mar-
keting authorization holder, legal supply status, and certain
pharmaceutical particulars (eg, shelf life and storage condi-
tions).44 Such harmonization approaches would effectively
decrease the off-label use of medicines in member states.
Conclusion
This is the first study to investigate the relationship between
registration procedures in a specific member state and off-label
prescribing in its territory. While acknowledging that off-label
prescribing by physicians is multifactorial, the authors found
that for Malta, the principal registration route that potentially
contributes to off-label prescribing in children relates to article
126a of Directive 2001/83/EC.
The regulation of medicinal products does not halt upon the
granting of a marketing authorization license. It is the obliga-
tion of all marketing authorization holders, member states, as
well as the European Commission and EMA to ensure that
transnational safe and effective prescribing practices are pro-
moted throughout the marketing authorization life cycle of
medicines. Pursuant to this, periodic appraisals should be car-
ried out in order to harmonize the product literature with best
clinical practice guidelines. Furthermore, as advocated by other
authors, dosing recommendations for specific age groups
should be streamlined for medicines of the same therapeutic
class.46 In view of this, it is also strongly recommended that
European-wide referral procedures are triggered by member
states, including Malta, and any recommendations implemen-
ted in a timely manner.
It would be interesting if similar reviews are conducted in
other member states. Since Cyprus is also a frequent user of the
article 126a provision, it is recommended that Cyprus investi-
gates the relationship between this registration procedure and
off-label prescribing. It is also recommended that the relation-
ship between Article 11 of Directive 2001/83/EC and off-label
prescribing practices be reviewed in those member states that
adopt its provision, that is, Denmark, Finland, Iceland, Nether-
lands, Norway, and Sweden.
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